Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac renin-angiotensin systems

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 1 51-1, 2005, Pages

  Xiang, Wei ^a   Kong, Juan ^a   Chen, Songcang ^b   Cao, Li Ping ^a   Qiao, Guilin ^a   Zheng, Wei ^a   Liu, Wenhua ^a   Li, Xinmin ^a   Gardner, David G ^b   Li, Yan Chun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atrial natriuretic peptide; Captopril; Cardiomyocyte; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ATRIAL NATRIURETIC FACTOR; CALCITRIOL; CAPTOPRIL; MESSENGER RNA; MONOCLONAL ANTIBODY; RENIN; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CELL SIZE; CONTROLLED STUDY; FEMALE; GENE DISRUPTION; HEART FUNCTION; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART MUSCLE CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE LEVEL; WILD TYPE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; CAPTOPRIL; CARDIOMEGALY; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; RECEPTORS, CALCITRIOL; RENIN-ANGIOTENSIN SYSTEM;

EID: 19944425466     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00224.2004     Document Type: Article

References (43)

1. Baker KM, Booz GW, and Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54: 227-241, 1992.
2. Baker KM, Chernin MI, Wixson SK, and Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol Heart Circ Physiol 259: H324-H332, 1990.
3. Ballermann BJ, Zeidel ML, Gunning ME, and Brenner BM. Vaso-active peptides and the kidney. In: The Kidney (4th ed.), edited by Brenner BM and Rector FC. Philadelphia, PA: W. B. Saunders, 1991, p. 510-583.
4. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, and Hare JM. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416: 337-339, 2002.
5. Chen S, Wu J, Hsieh JC, Whitfleld GK, Jurutka PW, Haussler MR, and Gardner DG. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 31: 1338-1342, 1998.
6. Chien KR, Knowlton KU, Zhu H, and Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 5: 3037-3046, 1991.
7. De Simone G, Devereux RB, Camargo MJ, Wallerson DC, Sealey JE, and Laragh JH. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens 9: 216-222, 1996.
8. Dostal DE and Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor. Am J Hypertens 5: 276-280, 1992.
9. Fraga C, Blanco M, Vigo E, Segura C, Garcia-Caballero T, and Perez-Fernandez R. Ontogenesis of the vitamin D receptor in rat heart. Histochem Cell Biol 117: 547-550, 2002.
10. Goldblatt H, Lynch J, Hanzal RF, and Summerville WW. Studies on experimental hypertension. I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 59: 347-379, 1934.
11. Gyurko R, Kuhlencordt P, Fishman MC, and Huang PL. Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J Physiol Heart Circ Physiol 278: H971-H981, 2000.
12. Heller LJ, Opsahl JA, Wernsing SE, Saxena R, and Katz SA. Myocardial and plasma renin-angiotensinogen dynamics during pressure-induced cardiac hypertrophy. Am J Physiol Regul Integr Comp Physiol 274: R849-R856, 1998.
13. Jurkovicova D, Dobesova Z, Kunes J, and Krizanova O. Different expression of renin-angiotensin system components in hearts of normotensive and hypertensive rats. Physiol Res 50: 35-42, 2001.
14. Kim S and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2000.
15. Kong J and Li YC. Effect of angiotensin II type I receptor antagonist and angiotensin-converting enzyme inhibitor on vitamin D receptor null mice. Am J Physiol Regul Integr Comp Physiol 285: R255-R261, 2003.
16. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19: 3998, 1991.
17. Lavoie JL and Sigmund CD. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144: 2179-2183, 2003.
18. Levin ER, Gardner DG, and Samson WK. Natriuretic peptides. N Engl J Med 339: 321-328, 1998.
19. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, and Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002.
20. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, and Demay MB. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94: 9831-9835, 1997.
21. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, and Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 89-90: 387-392, 2004.
22. Makino N, Sugano M, Otsuka S, and Hata T. Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 30: 796-802, 1997.
23. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, and Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 31: 1324-1330, 1998.
24. Naito Y, Tsujino T, Fujioka Y, Ohyanagi M, and Iwasaki T. Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats. Hypertension 40: 827-833, 2002.
25. Nakamura F, Nagano M, Higaki J, Higashimori K, Morishita R, Mikami H, and Ogihara T. The angiotensin-converting enzyme inhibitor, perindopril, prevents cardiac hypertrophy in low-renin hypertensive rats. Clin Exp Pharmacol Physiol 20: 135-140, 1993.
26. 3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol Heart Circ Physiol 272: H1751-H1758, 1997.
27. Parker TG. Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling. New Horiz 3: 288-300, 1995.
28. Prescott G, Silversides DW, and Reudelhuber TL. Tissue activity of circulating prorenin. Am J Hypertens 15: 280-285, 2002.
29. Sadoshima J, Xu Y, Slayter HS, and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-984, 1993.
30. Sano H, Okamoto H, Kitabatake A, Iizuka K, Murakami T, and Kawaguchi H. Increased mRNA expression of cardiac renin-angiotensin system and collagen synthesis in spontaneously hypertensive rats. Mol Cell Biochem 178: 51-58, 1998.
31. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, and Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 93: 13176-13181, 1996.
32. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, and Nishizawa Y. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19: 179-184, 2004.
33. Simpson RU, Thomas GA, and Arnold AJ. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem 260: 8882-8891, 1985.
34. Tamura K, Umemura S, Nyui N, Yamakawa T, Yamaguchi S, Ishigami T, Tanaka S, Tanimoto K, Takagi N, Sekihara H, Murakami K, and Ishii M. Tissue-specific regulation of angiotensinogen gene expression in spontaneously hypertensive rats. Hypertension 27: 1216-1223, 1996.
35. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003.
36. Tom B, Dendorfer A, and Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 35: 792-801, 2003.
37. 3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol Endocrinol Metab 258: E134-E142, 1990.
38. Weishaar RE and Simpson RU. The involvement of the endocrine system in regulating cardiovascular function: emphasis on vitamin D3. Endocr Rev 10: 351-365, 1989.
39. Weishaar RE and Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 79: 1706-1712, 1987.
40. Wolf K and Kurtz A. Renal artery stenosis rapidly enhances atrial natriuretic peptide gene expression. Hypertension 26: 1011-1017, 1995.
41. 3 suppresses expression and secretion of atrial natriuretic peptide from cardiac myocytes. Am J Physiol Endocrinol Metab 268: E1108-E1113, 1995.
42. 3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 97: 1577-1588, 1996.
43. Yang XP, Liu YH, Shesely EG, Bulagannawar M, Liu F, and Carretero OA. Endothelial nitric oxide gene knockout mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 34: 24-30, 1999.